273
We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.
 a patient with previously diagnosed CLL in minimal residual disease status: Subject; AML: Effect; lung cancer: Effect; fludarabine: Treatment; autologous peripheral blood stem-cell transplantation: Treatment; CLL in minimal residual disease status: Treatment.Disorder; fludarabine: Treatment.Drug; autologous peripheral blood stem-cell: Treatment.Drug; transplantation: Treatment.Route; fludarabine: Combination.Drug; autologous peripheral blood stem-cell: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with previously diagnosed CLL in minimal residual disease status: Subject; AML: Effect; lung cancer: Effect; fludarabine: Treatment; autologous peripheral blood stem-cell transplantation: Treatment; CLL in minimal residual disease status: Treatment.Disorder; fludarabine: Treatment.Drug; autologous peripheral blood stem-cell: Treatment.Drug; transplantation: Treatment.Route; fludarabine: Combination.Drug; autologous peripheral blood stem-cell: Combination.Drug